The impact of medicines for weight loss on cancer risk in a new study

The medications for weight loss and bariatric surgery have found effective to help people lose excessive pounds, and now a new study explores their link with the risk of cancer (ORC) related to obesity.

Obesity is a known risk factor for certain types of cancers, and it has also been shown that cancer survival impacts.

Obesity -related cancers include multiple myeloma, meningioma, adenocarcinoma of the esophagus; Stomach duct, colorectal, liver or biliary, gallbladder, pancreas, uterus, ovary, kidney kidney cancer, thyroid and postmenopausal breast cancer, according to the centers for disease control and prevention (CDC).

It was discovered that semaglutida has a shocking benefit for patients with liver disease in a new study

CLALIT HEALTH SERVICES researchers in Tel Aviv, Israel, conducted an observational study of the medical records of 6,356 participants of 24 years or more who had obesity and diabetes, without a history of cancer related to obesity.

Between 2010 and 2018, half of the participants took agonists from the GLP-1 receiver (LPG-1 ras)-injectable medicals for obesity and type 2 diabetes, with at least six drug purchases within 12 months. The other half underwent bariatric metabolic surgery (BMS).

In general, the study determined that “the direct effect of LPG1-RAS compared to BMS on the risk of ORC beyond its effects on weight loss is estimated as a relative risk reduction of 41%.”

Here is why belly fat is more common as we age, and 3 ways to prevent it

The findings were published in the Eclinical Medicine magazine.

“The results point to the existence of additional routes beyond the weight loss in which LPG-1RA contributes to the decrease in the risk of cancer related to obesity,” said News Digital, author of the main study, Yael Wolff Sagy, PHD, Chief of Research of Clalit Health Services.

How do the risk of LPG-1 cancer affect?

Niketa Patel, professor of molecular medicine with the Faculty of Morsani Medicine of the USF Health Morsani in Tampa, Florida, said that obesity is associated with chronic inflammation.

“It has been shown that LPG1-RAS reduces inflammation and, therefore, decreases the risk of developing ORC,” Digital’s News told News. (Patel did not participate in the study).

“The anti -inflammatory properties of these medications address a known risk factor for various types of cancer.”

“In a nutshell: obesity can cause certain cancers, and the treatment of obesity with LPG1-RA reduces the risk of only cancers related to obesity.”

Dr. Britta Reierson, MD, medical director of Knowwell, provider of metabolic health services, said there are several ways in which LPG-1 ras could have cancer mitigation properties.

“First, the anti -inflammatory properties of these medications address a known risk factor for various types of cancer,” said Minnesota’s headquarters, which was not part of the research, News Digital.

“Secondly, metabolic regulation and improvement in the metabolic health of these medications, including the reduction of blood glucose levels and decreased insulin resistance, can reduce the risk of cancer.”

Emerging evidence also suggests that RA LPG-1 can have direct antitumor effects, said Reierson: “Potentially through the modulation of immune responses and epigenetic changes (changes that occur to gene expression and are transmitted to future generations).”

First GLP-1 pills to lose weight, diabetes shows success in the late phase trial

Research suggests that GLP-1 medications help reduce inflammation not only through weight loss, but also in other body organs, such as the heart, according to Dr. Susan Savery, MD, a medical doctor of obesity certified by the Board and a primary care doctor with luxury care, a virtual health platform that offers primary care, therapy and weight management services.

“Over time, chronic inflammation can be a risk factor for cancer development, since it can damage cell DNA,” Digital News told News, based in San Francisco, who did not participate in the study.

“Our fatty cells (adipose tissue) naturally produce inflammatory cells, and GLP-1 medications, similar to bariatric surgery, help reduce this inflammation by decreasing the amount of adipose tissue through weight loss.”

Potential limitations

The study had some limitations, the researchers recognized.

“First, it is an observational study. It means that our comparison groups (people who underwent surgery versus those who received LPG1-RAS) can still have some residual differences, despite our methodological efforts,” Sagy told News Digital.

Click here to get the News application

“However, only this type of real life study can provide the long monitoring period that is necessary to assess the risk of developing cancer, which often has very long latency periods.”

Another limitation is that the primary drug included in the study was the liraglutida (Saxenda, Victoza), with a smaller number of people who take exenatida (Byetta) and Dreamaglutida (Trulicity).

“It will be important to evaluate the comparative effectiveness of the newest GLP1-ra, which is expected to have a greater effect,” said Sagy.

“Although the direction of the results is promising, we must wait and see if the clinical guidelines and how they will consider it.”

Click here to register in our health newsletter

Reierson agreed that much more research is needed before LPG-1 ras could be considered as cancer prevention options.

“The largest, random and controlled controlled tests are necessary to confirm the observed effects and better understand the underlying mechanisms,” he said.

“It will also be important to investigate the impact of the GLP-1 on different types of cancer and evaluate long-term safety and possible side effects of the use of LPG-1 ra as cancer therapy.”

Savery agrees that it is likely to be too soon to predict FDA approval for cancer therapy, but noted that “weight reduction plays an important role in cancer prevention, and LPG-1 seem to offer an additional benefit through inflammation reduction.”

For more health articles, visit www.Newsnews.com/health

While RAGLP-1 are “wonderful tools” that can support people on weight loss trips, Savery said that maintaining a healthy lifestyle through a nutritional diet and regular physical activity is “the basis for cancer prevention and better general health.”